Chambers Review
Provided by Chambers
Chambers France
Private Equity: Mid-Market - France
Individual Editorial
Diana Hund assists leading private equity clients with acquisitions and investments.
Diana Hund
France Guide 2025
Band 3 : Private Equity: Mid-Market
Email address
[email protected]Contact number
+33 1 81 69 15 50Share profile
Lawyers profile
France 2025
Lawyers profile | France 2025: Private Equity: Mid-Market
Diana Hund
Ranked in 1 Practice Areas
Band 3
Ranked in Guides
About
Provided by Diana Hund
France
Practice Areas
Diana Hund advises clients on a wide variety of corporate transactions, including domestic and cross-border mergers and acquisitions, and leveraged buyouts.
Diana represents private equity sponsors, founders and managers in connection with acquisitions and disposals. She also represents German corporate groups in their investments in French companies and other cross-border transactions. In addition, Diana advises venture capital funds, corporate clients and entrepreneurs on venture capital and growth transactions of various types in sectors such as e-commerce and technology.
Strengths
Provided by Chambers
Slide 1 of 2
Diana is always incredibly responsive and empowers her team. It feels safe working with her. She is a real asset in closing deals.
Diana is an outstanding lawyer with a pragmatic, deal-centric and client-centric approach. She is technically strong, and creative in problem-solving situations and negotiations.
Slide 2 of 2
She is a very nice person, very responsive, rigorous and committed.
Diana is always incredibly responsive and empowers her team. It feels safe working with her. She is a real asset in closing deals.
Diana is an outstanding lawyer with a pragmatic, deal-centric and client-centric approach. She is technically strong, and creative in problem-solving situations and negotiations.
She is a very nice person, very responsive, rigorous and committed.
Discover other Lawyers at
McDermott Will & Emery
Provided by Chambers
Filter by
Band
France
Banking & Finance
Pharma/Life Sciences: Corporate
Private Equity: Mid-Market
Tax
